Cannabis Research

A novel medical science company

FREE Q&A with Dr. Ethan Russo

by

Q&A Thursday December 15, 2022 at 11 PST| 2 EST for a one-hour Q&A session.

Dr. Ethan Russo hosts FREE cannabis Q&A

Dr. Ethan Russo answered questions about:

  • The cannabis plant
  • Cannabinoids
  • Terpenes
  • Endocannabinoid System (ECS)
  • Existing cannabis and ECS research
  • Areas of needed research
  • How cannabis and cannabis products benefit certain disease states and symptoms
  • Opportunities for new product development

The goal is for patients, caregivers, medical professionals, industry people, advocates and the general public to have a forum to ask general questions. Please note, specific questions about individual treatment and formulation will not be addressed. We cannot promise to answer every question but will do our best to cover as much information as possible.

This webinar has been made available for purchase to download here: https://buycredo.mm411.com/

Hemp Roots: A Neglected Therapeutic Resource

by

During our 4th webinar with Dr. Ethan Russo, the topic was “Hemp Roots: A Neglected Therapeutic Resource.” The webinar will took place on Thurs., March 31st at 11am PST/2pm EST via Zoom.

Purchase the webinar on demand here: https://buycredo.mm411.com/

The webinar addressed:

1) Hemp roots have been used traditionally for therapeutic purposes for thousands of years.

2) Indications for hemp roots parallel those for hemp flowers despite a total lack of biochemical overlap

3) We will examine the anti-inflammatory and anti-cancer properties of hemp root triterpenoids and alkaloids

Who attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

The on-demand webinar can be purchased here: https://buycredo.mm411.com/

Webinar: Plants and the Endocannabinoid System

by

During our 4th webinar with Dr. Ethan Russo, the topic was “Plants and the Endocannabinoid System”. The webinar took place Thur, Feb 24th at 11am PST/2pm EST.

Purchase the webinar ondemand here: https://buycredo.mm411.com/

This webinar addressed:

  1. Cannabis is one plant among many that affect the human endocannabinoid system (ECS)
  2. Other plants may affect the CB1 receptor directly, or affect endocannabinoid metabolism indirectly
  3. Even common foodstuffs (e.g., carrots, chocolate, black pepper, and prebiotic fibers) can affect endocannabinoid tone
  4. Join us to learn how your diet affects the ECS!

Who attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

The on-demand webinar is $22.50 and is paid via PayPal. https://buycredo.mm411.com/

A susceptibility test for the mysterious cannabinoid hyperemesis syndrome (CHS) is now available.

by

January 18, 2022

Austin, TX – CReDO Science and EndoCanna Health are delighted to partner to provide a screening test for cannabinoid hyperemesis syndrome (CHS). CReDO Science CEO and the inventor of the screening technology, Ethan Russo, M.D. says, “CHS previously has been an enigmatic disorder that has been a tremendous burden of abdominal pain, nausea, and vomiting for its patients. Simultaneously, it has been a diagnostic dilemma for hospital emergency departments that attempt to decipher its diagnosis with various expensive and sometimes invasive tests that usually provide little insight to the problem.”

Dr. Russo has been seeking to understand the origins of CHS for years. In 2019, his company approached Len May, the CEO of EndoCanna Health, where Dr. Russo serves as a Scientific Advisory Board member, to find that they, too, cared about solving the mystery of CHS. Dr. Russo designed and oversaw a research study executed and analyzed by EndoCanna Health which led to the discovery of five genes that appear to occur in CHS patients at significantly higher rates than the general population.  Where an individual has two or more of the five genes, it is an indication they are at much greater risk for CHS, which is triggered by chronic consumption of high THC cannabis and cannabis products.

Mr. May explains, “With the advent of this new technology, an inexpensive, simple mouth swab may provide insight to patients, their families, and physicians as to the source of the problem, and its impact.” Dr. Russo explains further the importance of this screening tool, “Our research has provided the understanding of CHS as a genetic susceptibility, and one that has implications for risks for other disorders including alcoholism, addiction to other substances, and risks for future development of heart disease and dementia, among others.”

We believe this technology will have important public health implications and offer significant savings in cost expenditures for unnecessary diagnostic tests, which patients surveyed have reported reaching $90,000-100,000. Highlighting the party’s collective intent to serve patients, Mr. May points out, “Through our HIPPA compliant process, we are able to provide the privacy patients desire with important data physicians need to aid in diagnosis and to educate patients about recovery.”

It is estimated approximately 50,000 people a year develop CHS.  That figure is expected to increase significantly as cannabis legalization occurs across more jurisdictions globally.  Some estimates for CHS prevalence have been as high as 2 million patients in the U.S., but no one knows.

Tests can be ordered by patients and physicians through the sales portal  https://shop.endodna.com/products/chs-dna-susceptibility-test. Additional information about CHS is available at www.what-is-chs.com.

CReDO Science LLC is a biopharma holding company that exists to solve problems of the human/animal ECS including developing optimized formulations from the Cannabis plant for better living. Learn more at www.credo-science.com.

Endocanna Health is the industry leader in endocannabinoid system genomic testing and the manufacturer of genetically aligned formulations that create optimal cannabis experiences. Learn more at www.endodna.com.

###

Cannabinoid Hyperemesis Syndrome (CHS) Webinar

by

During our 3rd webinar with Dr. Ethan Russo, the topic was “Cannabinoid Hyperemesis Syndrome (CHS)”. The webinar took place Thur, Jan 20th at 11am PST/2pm EST. You can now watch the recorded webinar on-demand. Click here to see to see details and purchasing info here: https://buycredo.mm411.com/

This webinar addressed:

  1. History and signs and symptoms of cannabinoid hyperemesis syndrome (CHS)
  2. Results of the largest CHS study to date: survey responses and genomic analysis with its implications
  3. Some thoughts on treatment and future direction for CHS research

Who Attended?

Patients, medical professionals, cannabis researchers, industry innovators, advocates and cannabis educators.

The webinar took place over Zoom with a 30 minute presentation by Dr. Ethan Russo followed up by a 30 minute Q&A session.

For online access to the webinar, click here for purchasing info: https://buycredo.mm411.com/

New Course Offering

Cannabis Therapeutics Course Badge

Foundations of Therapeutics with Ethan Russo, MD: An Evidence-Based Medical Cannabis Education Course

The site is for business-related activities for CReDO Science. It is not for diagnosing or treating specific conditions or finding referrals. People seeking such care should find a practitioner here: Find a Practitioner – Society of Cannabis Clinicians